TrialSignal
Clinical trial intelligence report
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02880956-Jul 28, 2026
NCT ID
NCT02880956
Status
COMPLETED
Phase
Phase 2
Sponsor
AbbVie
Executive brief
Investment-Ready Snapshot
ABBV-8E12, an investigational therapy by AbbVie, is positioned in the competitive landscape of Alzheimer's Disease treatments, particularly targeting early stages of the disease. The market for Alzheimer's therapies is expanding, driven by increasing prevalence and demand for effective treatments. AbbVie's focus on tau pathology may provide a differentiated approach compared to existing amyloid-targeting therapies. The successful completion of this Phase 2 trial may enhance AbbVie's portfolio and attract partnerships or acquisitions, given the high unmet need in this therapeutic area.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02880956
Indication
Alzheimer's Disease
Modality
small molecule
Target
Tau protein (specifically targeting tauopathies associated with Alzheimer's Disease)
Intervention
ABBV-8E12, placebo for ABBV-8E12
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.